-transparent.png){kind=logo}
Two patients with persistent minimal ovarian cancer after conventional polychemotherapy were treated with high doses of cyclophosphamide and VP 16-213 followed by autologous bone marrow infusion. Ten months afterward no clinical signs of tumor were apparent. In one patient the complete response was surgically documented. Toxicity included cardiac and pulmonary arrest during marrow infusion in one patient, but was otherwise manageable. This method of late intensification of chemotherapy in patients with persisting ovarian cancer merits further investigation.
Related Publications
R Vriesendorp, and
J G Aalders, and
D T Sleijfer, and
P E Postmus, and
P H Willemse, and
J Bouma, and
N H Mulder
January 1989,
Gynecologic and obstetric investigation,
R Vriesendorp, and
J G Aalders, and
D T Sleijfer, and
P E Postmus, and
P H Willemse, and
J Bouma, and
N H Mulder
February 1993,
Bulletin du cancer,
R Vriesendorp, and
J G Aalders, and
D T Sleijfer, and
P E Postmus, and
P H Willemse, and
J Bouma, and
N H Mulder
April 1989,
European journal of cancer & clinical oncology,
R Vriesendorp, and
J G Aalders, and
D T Sleijfer, and
P E Postmus, and
P H Willemse, and
J Bouma, and
N H Mulder
March 1977,
European journal of cancer,
R Vriesendorp, and
J G Aalders, and
D T Sleijfer, and
P E Postmus, and
P H Willemse, and
J Bouma, and
N H Mulder
September 1984,
Cancer,
R Vriesendorp, and
J G Aalders, and
D T Sleijfer, and
P E Postmus, and
P H Willemse, and
J Bouma, and
N H Mulder
January 1979,
Experimental hematology,
R Vriesendorp, and
J G Aalders, and
D T Sleijfer, and
P E Postmus, and
P H Willemse, and
J Bouma, and
N H Mulder
January 1988,
Progress in clinical and biological research,
R Vriesendorp, and
J G Aalders, and
D T Sleijfer, and
P E Postmus, and
P H Willemse, and
J Bouma, and
N H Mulder
January 1992,
JAMA,
R Vriesendorp, and
J G Aalders, and
D T Sleijfer, and
P E Postmus, and
P H Willemse, and
J Bouma, and
N H Mulder
March 1993,
Journal belge de radiologie,
R Vriesendorp, and
J G Aalders, and
D T Sleijfer, and
P E Postmus, and
P H Willemse, and
J Bouma, and
N H Mulder
March 1996,
Lancet (London, England),
